Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-01 · accession 0000950170-25-032263 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-04 | 2025-03-04 | NTLA | Clark Eliana | EVP, Chief Technical Off | S - Sale | $8.99 | -679 | 95.4K | -0.7% | -$6,104 |
| D | 2025-03-04 | 2025-03-01 | NTLA | Clark Eliana | EVP, Chief Technical Off | A - Grant | $0.00 | +32.0K | 96.0K | +50% | $0 |
| D | 2025-03-04 | 2025-03-01 | NTLA | Clark Eliana | EVP, Chief Technical Off | A - Grant | $0.00 | +45.7K | 45.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | S | D | 679 | $8.99 | 95,369 | D | — | — | |
| 2 | Common | Common Stock | 2025-03-01 | A | A | 32,000 | $0.00 | 96,048 | D | — | — | (F1) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| 3 | Derivative | Stock Option (right to buy) | 2025-03-01 | A | A | 45,714 | $0.00 | 45,714 | D | $10.09 · — to 2035-02-28 | 45,714 Common Stock | (F3) This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. |